{"id":802933,"date":"2026-05-17T13:35:15","date_gmt":"2026-05-17T13:35:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/802933\/"},"modified":"2026-05-17T13:35:15","modified_gmt":"2026-05-17T13:35:15","slug":"new-drug-stops-progression-of-kidney-cancer","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/802933\/","title":{"rendered":"New Drug Stops Progression of Kidney Cancer"},"content":{"rendered":"

SadaNews – An American clinical study has shown promising results for a new experimental immunotherapy drug, which may represent an important step in treating advanced kidney cancer.<\/strong><\/p>\n

Researchers from Yale University indicated that the new drug successfully reduced tumors and halted disease progression in several patients. The results were published on Thursday in the journal “Cell Reports.” <\/p>\n

Advanced kidney cancer is a late-stage form of the disease where the tumor extends beyond the kidney or spreads to other organs, such as the lungs, bones, or liver. In this stage, treatment becomes more complicated as surgery alone may not be sufficient, and doctors typically rely on systemic therapies, such as immunotherapy, to control disease growth and slow its spread.<\/p>\n

The team tested a new type of immunotherapy on more than 100 patients with various types of cancer between 2021 and 2024, most of whom had undergone multiple treatments without achieving an effective response. The study focused specifically on advanced renal cell carcinoma, the most common and aggressive type of kidney cancer.<\/p>\n

The trial included 22 patients with this type of cancer, whose tumors continued to progress despite receiving standard treatments. The results showed that the drug led to complete remission in one patient and reduced tumor size in two others, while the disease remained stable in three patients for an extended period, with one case lasting up to 25 months.<\/p>\n

Immunotherapy relies on stimulating the immune system to attack cancer cells, but tumors often evade immune attack by exploiting what are known as “immune checkpoints,” which are natural mechanisms that prevent the immune system from overactive responses that could cause inflammation or autoimmune diseases.<\/p>\n

Some modern immunotherapy treatments work by disabling these “checkpoints,” allowing immune cells to attack the tumor more effectively.<\/p>\n

The new drug targets a protein known as “HPK1,” which is one of the factors that inhibits the activity of immune cells, including T cells. This protein is found inside various types of immune cells, making it a scientifically complex challenge to target.<\/p>\n

Researchers noted that this challenge arises from the protein’s presence inside the cell rather than on its surface, in addition to its structural similarity to other essential proteins, complicating the development of a drug that accurately targets it without affecting other cellular functions.<\/p>\n

Nonetheless, the team was able to develop a drug capable of entering immune cells and disabling the “HPK1” protein, contributing to the restoration of the immune system’s ability to attack cancer cells.<\/p>\n

To ensure accurate targeting, researchers used blood samples from patients to develop a test measuring biomarkers associated with protein inhibition, and the results indicated that the drug successfully disabled it within T cells.<\/p>\n

Researchers concluded that these results represent an important step toward developing more effective immunotherapies, which may contribute in the future to controlling cancer and possibly achieving higher remission rates in patients with advanced tumors.<\/p>\n","protected":false},"excerpt":{"rendered":"SadaNews – An American clinical study has shown promising results for a new experimental immunotherapy drug, which may…\n","protected":false},"author":3,"featured_media":802934,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,67,132,68],"class_list":{"0":"post-802933","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116590184695843997","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/802933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=802933"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/802933\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/802934"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=802933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=802933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=802933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}